Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2010

View Archived Issues

Preclinical and first-in-human data reported on GSK-1292263 for type 2 diabetes

PCDH10 gene methylation status is biomarker for risk of cervical cancer in hrHPV infection

A-918446 and A-801195 show preclinical promise for treatment of AD

Biomarkers of oxidative stress correlate with HPV clearance

Taspoglutide is superior to comparators in improving glycemic control in phase III diabetes trials

Mesoblast to manufacture and supply adult stem cell products in Australia

Lilly acquires Alnara Pharmaceuticals

Prolor Biotech's hGH-CTP enters phase II trial in growth hormone deficiency

Access Pharma and BioScrip sign MuGard distribution agreement

Novartis' Rasilez approved in China for high blood pressure

Pharmasset claims new NS5B inhibitors

Merck & Co. discloses new gamma-secretase modulators

Health Canada grants priority review for Prochymal NDS

New PLK-1 inhibitors discovered by Rigel

Gilead Sciences reports highlights of second quarter 2010

Sirtris Pharmaceuticals describes new sirtuin modulators

Curis identifies novel CDK inhibitors

Abbott updates developments of second quarter 2010

Ampio begins phase II trial of oral Optina in diabetic macular edema

Fera Pharmaceuticals acquires itraconazole topical suspension

GSK suspends enrollment in TIDE trial at FDA's request

Tamir agents are efficacious against SARS virus in vitro

Onyx begins phase III carfilzomib combination trial in relapsed multiple myeloma

FDA recommends further naproxcinod trials in complete response letter to NicOx

Preliminary phase IIb data disclosed on S/GSK-1349572 for HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...